Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression

The associated increase in the lipopolysaccharide (LPS) levels and uremic toxins in chronic kidney disease (CKD) has shifted the way we focus on intestinal microbiota. This study shows that a disruption of the intestinal barrier in CKD promotes leakage of LPS from the gut, subsequently decreasing in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology, dialysis, transplantation dialysis, transplantation, 2019-05, Vol.34 (5), p.783-794
Hauptverfasser: Gonzalez, Austin, Krieg, Richard, Massey, Hugh D, Carl, Daniel, Ghosh, Shobha, Gehr, Todd W B, Ghosh, Siddhartha S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 794
container_issue 5
container_start_page 783
container_title Nephrology, dialysis, transplantation
container_volume 34
creator Gonzalez, Austin
Krieg, Richard
Massey, Hugh D
Carl, Daniel
Ghosh, Shobha
Gehr, Todd W B
Ghosh, Siddhartha S
description The associated increase in the lipopolysaccharide (LPS) levels and uremic toxins in chronic kidney disease (CKD) has shifted the way we focus on intestinal microbiota. This study shows that a disruption of the intestinal barrier in CKD promotes leakage of LPS from the gut, subsequently decreasing insulin sensitivity. Butyrate treatment improved the intestinal barrier function by increasing colonic mucin and tight junction (TJ) proteins. This modulation further ameliorated metabolic functions such as insulin intolerance and improved renal function. Renal failure was induced by 5/6th nephrectomy (Nx) in rats. A group of Nx and control rats received sodium butyrate in drinking water. The Nx groups were compared with sham-operated controls. The Nx rats had significant increases in serum creatinine, urea and proteinuria. These animals had impaired glucose and insulin tolerance and increased gluconeogenesis, which corresponded with decreased glucagon-like peptide-1 (GLP-1) secretion. The Nx animals suffered significant loss of intestinal TJ proteins, colonic mucin and mucin 2 protein. This was associated with a significant increase in circulating LPS, suggesting a leaky gut phenomenon. 5'adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, known to modulate epithelial TJs and glucose metabolism, was significantly reduced in the intestine of the Nx group. Anti-inflammatory cytokine, interleukin 10, anti-bacterial peptide and cathelicidin-related antimicrobial peptide were also lowered in the Nx cohort. Butyrate treatment increased AMPK phosphorylation, improved renal function and controlled hyperglycemia. Butyrate improves AMPK phosphorylation, increases GLP-1 secretion and promotes colonic mucin and TJ proteins, which strengthen the gut wall. This decreases LPS leakage and inflammation. Taken together, butyrate improves metabolic parameters such as insulin resistance and markers of renal failure in CKD animals.
doi_str_mv 10.1093/ndt/gfy238
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6503301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2084920523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-4a3f3b8428731e302efc9f198d6778cfc59af2cf1650d6eb4ccf7f5e26ddd78b3</originalsourceid><addsrcrecordid>eNpVkc2OFCEUhYnROD2jGx_AsDQm5fBTvxsT0zpqnMSFuiYUXFoMBS0UxnoCX9s79jjRFYecc78LOYQ84ewFZ5O8jHa9PLhNyPEe2fG2Zw3K7j7Zockb1rHpjJyX8o0xNolheEjOJGNjJ6ZhR359StbXhc513bJegeoFgk83slAfSw0-0gzFl1VHg3a0eI06UKd9qBkwRPcfXlOcKHTe6JJsDXr18YAOQlBh-Ah5AT374NftD2OpBgfh5xHZxaf4iDxwOhR4fHtekC9Xbz7v3zXXH9--37-6bkzbtmvTaunkPLZiHCQHyQQ4Mzk-jbYfhtE4003aCeN43zHbw9wa4wbXgeittcM4ywvy8sQ91nkBayCuWQd1zH7ReVNJe_W_E_1XdUg_FAKlZBwBz24BOX2v-D-1-GIgBB0h1aIEG9tJsE5IjD4_RU1OpWRwd2s4UzfNKWxOnZrD8NN_H3YX_VuV_A3qEprr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2084920523</pqid></control><display><type>article</type><title>Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Gonzalez, Austin ; Krieg, Richard ; Massey, Hugh D ; Carl, Daniel ; Ghosh, Shobha ; Gehr, Todd W B ; Ghosh, Siddhartha S</creator><creatorcontrib>Gonzalez, Austin ; Krieg, Richard ; Massey, Hugh D ; Carl, Daniel ; Ghosh, Shobha ; Gehr, Todd W B ; Ghosh, Siddhartha S</creatorcontrib><description>The associated increase in the lipopolysaccharide (LPS) levels and uremic toxins in chronic kidney disease (CKD) has shifted the way we focus on intestinal microbiota. This study shows that a disruption of the intestinal barrier in CKD promotes leakage of LPS from the gut, subsequently decreasing insulin sensitivity. Butyrate treatment improved the intestinal barrier function by increasing colonic mucin and tight junction (TJ) proteins. This modulation further ameliorated metabolic functions such as insulin intolerance and improved renal function. Renal failure was induced by 5/6th nephrectomy (Nx) in rats. A group of Nx and control rats received sodium butyrate in drinking water. The Nx groups were compared with sham-operated controls. The Nx rats had significant increases in serum creatinine, urea and proteinuria. These animals had impaired glucose and insulin tolerance and increased gluconeogenesis, which corresponded with decreased glucagon-like peptide-1 (GLP-1) secretion. The Nx animals suffered significant loss of intestinal TJ proteins, colonic mucin and mucin 2 protein. This was associated with a significant increase in circulating LPS, suggesting a leaky gut phenomenon. 5'adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, known to modulate epithelial TJs and glucose metabolism, was significantly reduced in the intestine of the Nx group. Anti-inflammatory cytokine, interleukin 10, anti-bacterial peptide and cathelicidin-related antimicrobial peptide were also lowered in the Nx cohort. Butyrate treatment increased AMPK phosphorylation, improved renal function and controlled hyperglycemia. Butyrate improves AMPK phosphorylation, increases GLP-1 secretion and promotes colonic mucin and TJ proteins, which strengthen the gut wall. This decreases LPS leakage and inflammation. Taken together, butyrate improves metabolic parameters such as insulin resistance and markers of renal failure in CKD animals.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfy238</identifier><identifier>PMID: 30085297</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Animals ; Butyric Acid - pharmacology ; Disease Models, Animal ; Histamine Antagonists - pharmacology ; Immunohistochemistry ; Insulin Resistance - physiology ; Intestinal Mucosa - metabolism ; Male ; Mucins - biosynthesis ; ORIGINAL ARTICLES ; Permeability ; Rats ; Renal Insufficiency, Chronic - drug therapy ; Renal Insufficiency, Chronic - metabolism</subject><ispartof>Nephrology, dialysis, transplantation, 2019-05, Vol.34 (5), p.783-794</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.</rights><rights>The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-4a3f3b8428731e302efc9f198d6778cfc59af2cf1650d6eb4ccf7f5e26ddd78b3</citedby><cites>FETCH-LOGICAL-c444t-4a3f3b8428731e302efc9f198d6778cfc59af2cf1650d6eb4ccf7f5e26ddd78b3</cites><orcidid>0000-0002-7793-6945</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30085297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez, Austin</creatorcontrib><creatorcontrib>Krieg, Richard</creatorcontrib><creatorcontrib>Massey, Hugh D</creatorcontrib><creatorcontrib>Carl, Daniel</creatorcontrib><creatorcontrib>Ghosh, Shobha</creatorcontrib><creatorcontrib>Gehr, Todd W B</creatorcontrib><creatorcontrib>Ghosh, Siddhartha S</creatorcontrib><title>Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol Dial Transplant</addtitle><description>The associated increase in the lipopolysaccharide (LPS) levels and uremic toxins in chronic kidney disease (CKD) has shifted the way we focus on intestinal microbiota. This study shows that a disruption of the intestinal barrier in CKD promotes leakage of LPS from the gut, subsequently decreasing insulin sensitivity. Butyrate treatment improved the intestinal barrier function by increasing colonic mucin and tight junction (TJ) proteins. This modulation further ameliorated metabolic functions such as insulin intolerance and improved renal function. Renal failure was induced by 5/6th nephrectomy (Nx) in rats. A group of Nx and control rats received sodium butyrate in drinking water. The Nx groups were compared with sham-operated controls. The Nx rats had significant increases in serum creatinine, urea and proteinuria. These animals had impaired glucose and insulin tolerance and increased gluconeogenesis, which corresponded with decreased glucagon-like peptide-1 (GLP-1) secretion. The Nx animals suffered significant loss of intestinal TJ proteins, colonic mucin and mucin 2 protein. This was associated with a significant increase in circulating LPS, suggesting a leaky gut phenomenon. 5'adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, known to modulate epithelial TJs and glucose metabolism, was significantly reduced in the intestine of the Nx group. Anti-inflammatory cytokine, interleukin 10, anti-bacterial peptide and cathelicidin-related antimicrobial peptide were also lowered in the Nx cohort. Butyrate treatment increased AMPK phosphorylation, improved renal function and controlled hyperglycemia. Butyrate improves AMPK phosphorylation, increases GLP-1 secretion and promotes colonic mucin and TJ proteins, which strengthen the gut wall. This decreases LPS leakage and inflammation. Taken together, butyrate improves metabolic parameters such as insulin resistance and markers of renal failure in CKD animals.</description><subject>Animals</subject><subject>Butyric Acid - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Histamine Antagonists - pharmacology</subject><subject>Immunohistochemistry</subject><subject>Insulin Resistance - physiology</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Male</subject><subject>Mucins - biosynthesis</subject><subject>ORIGINAL ARTICLES</subject><subject>Permeability</subject><subject>Rats</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Renal Insufficiency, Chronic - metabolism</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc2OFCEUhYnROD2jGx_AsDQm5fBTvxsT0zpqnMSFuiYUXFoMBS0UxnoCX9s79jjRFYecc78LOYQ84ewFZ5O8jHa9PLhNyPEe2fG2Zw3K7j7Zockb1rHpjJyX8o0xNolheEjOJGNjJ6ZhR359StbXhc513bJegeoFgk83slAfSw0-0gzFl1VHg3a0eI06UKd9qBkwRPcfXlOcKHTe6JJsDXr18YAOQlBh-Ah5AT374NftD2OpBgfh5xHZxaf4iDxwOhR4fHtekC9Xbz7v3zXXH9--37-6bkzbtmvTaunkPLZiHCQHyQQ4Mzk-jbYfhtE4003aCeN43zHbw9wa4wbXgeittcM4ywvy8sQ91nkBayCuWQd1zH7ReVNJe_W_E_1XdUg_FAKlZBwBz24BOX2v-D-1-GIgBB0h1aIEG9tJsE5IjD4_RU1OpWRwd2s4UzfNKWxOnZrD8NN_H3YX_VuV_A3qEprr</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Gonzalez, Austin</creator><creator>Krieg, Richard</creator><creator>Massey, Hugh D</creator><creator>Carl, Daniel</creator><creator>Ghosh, Shobha</creator><creator>Gehr, Todd W B</creator><creator>Ghosh, Siddhartha S</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7793-6945</orcidid></search><sort><creationdate>20190501</creationdate><title>Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression</title><author>Gonzalez, Austin ; Krieg, Richard ; Massey, Hugh D ; Carl, Daniel ; Ghosh, Shobha ; Gehr, Todd W B ; Ghosh, Siddhartha S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-4a3f3b8428731e302efc9f198d6778cfc59af2cf1650d6eb4ccf7f5e26ddd78b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Butyric Acid - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Histamine Antagonists - pharmacology</topic><topic>Immunohistochemistry</topic><topic>Insulin Resistance - physiology</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Male</topic><topic>Mucins - biosynthesis</topic><topic>ORIGINAL ARTICLES</topic><topic>Permeability</topic><topic>Rats</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Renal Insufficiency, Chronic - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez, Austin</creatorcontrib><creatorcontrib>Krieg, Richard</creatorcontrib><creatorcontrib>Massey, Hugh D</creatorcontrib><creatorcontrib>Carl, Daniel</creatorcontrib><creatorcontrib>Ghosh, Shobha</creatorcontrib><creatorcontrib>Gehr, Todd W B</creatorcontrib><creatorcontrib>Ghosh, Siddhartha S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez, Austin</au><au>Krieg, Richard</au><au>Massey, Hugh D</au><au>Carl, Daniel</au><au>Ghosh, Shobha</au><au>Gehr, Todd W B</au><au>Ghosh, Siddhartha S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol Dial Transplant</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>34</volume><issue>5</issue><spage>783</spage><epage>794</epage><pages>783-794</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><abstract>The associated increase in the lipopolysaccharide (LPS) levels and uremic toxins in chronic kidney disease (CKD) has shifted the way we focus on intestinal microbiota. This study shows that a disruption of the intestinal barrier in CKD promotes leakage of LPS from the gut, subsequently decreasing insulin sensitivity. Butyrate treatment improved the intestinal barrier function by increasing colonic mucin and tight junction (TJ) proteins. This modulation further ameliorated metabolic functions such as insulin intolerance and improved renal function. Renal failure was induced by 5/6th nephrectomy (Nx) in rats. A group of Nx and control rats received sodium butyrate in drinking water. The Nx groups were compared with sham-operated controls. The Nx rats had significant increases in serum creatinine, urea and proteinuria. These animals had impaired glucose and insulin tolerance and increased gluconeogenesis, which corresponded with decreased glucagon-like peptide-1 (GLP-1) secretion. The Nx animals suffered significant loss of intestinal TJ proteins, colonic mucin and mucin 2 protein. This was associated with a significant increase in circulating LPS, suggesting a leaky gut phenomenon. 5'adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, known to modulate epithelial TJs and glucose metabolism, was significantly reduced in the intestine of the Nx group. Anti-inflammatory cytokine, interleukin 10, anti-bacterial peptide and cathelicidin-related antimicrobial peptide were also lowered in the Nx cohort. Butyrate treatment increased AMPK phosphorylation, improved renal function and controlled hyperglycemia. Butyrate improves AMPK phosphorylation, increases GLP-1 secretion and promotes colonic mucin and TJ proteins, which strengthen the gut wall. This decreases LPS leakage and inflammation. Taken together, butyrate improves metabolic parameters such as insulin resistance and markers of renal failure in CKD animals.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30085297</pmid><doi>10.1093/ndt/gfy238</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-7793-6945</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0931-0509
ispartof Nephrology, dialysis, transplantation, 2019-05, Vol.34 (5), p.783-794
issn 0931-0509
1460-2385
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6503301
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Butyric Acid - pharmacology
Disease Models, Animal
Histamine Antagonists - pharmacology
Immunohistochemistry
Insulin Resistance - physiology
Intestinal Mucosa - metabolism
Male
Mucins - biosynthesis
ORIGINAL ARTICLES
Permeability
Rats
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - metabolism
title Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A07%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20butyrate%20ameliorates%20insulin%20resistance%20and%20renal%20failure%20in%20CKD%20rats%20by%20modulating%20intestinal%20permeability%20and%20mucin%20expression&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Gonzalez,%20Austin&rft.date=2019-05-01&rft.volume=34&rft.issue=5&rft.spage=783&rft.epage=794&rft.pages=783-794&rft.issn=0931-0509&rft.eissn=1460-2385&rft_id=info:doi/10.1093/ndt/gfy238&rft_dat=%3Cproquest_pubme%3E2084920523%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2084920523&rft_id=info:pmid/30085297&rfr_iscdi=true